Pfizer announced that the Centers for Medicare and Medicaid Services (CMS) will cover the cost of the company’s biosimilar Inflectra (infliximab-dyyb) for Medicare enrollees as a Part B-covered drug. Inflectra was approved by the FDA in April 2016 as a biosimilar to Janssen Biotech’s Remicade (infliximab) for reducing signs and symptoms in patients with rheumatoid arthritis, adult and pediatric Crohn’s disease, adult ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.
The CMS reimbursement price, which took effect January 1, 2017, is a 15% discount to the Wholesale Acquisition Cost (WAC) of Remicade. The WAC does not include discounts to payers, providers, distributors, and other purchasing organizations.
Inflectra is the first biosimilar monoclonal antibody, and the second biosimilar, to become available in the United States. The FDA’s approval of Inflectra as a biosimilar to Remicade did not include interchangeability with the reference drug; pharmacists cannot substitute Inflectra for Remicade without a physician’s instructions.
Pfizer announced the launch of the Pfizer enCompass program, a reimbursement service and patient support program offering coding and reimbursement support for providers, co-pay assistance to eligible patients who have commercial insurance that covers Inflectra, and financial assistance for eligible uninsured and underinsured patients.
Pfizer also announced the availability of pricing for 340B hospitals, a drug pricing program for eligible healthcare organizations that serve as safety net providers, including Medicare/Medicaid Disproportionate Share Hospitals, children’s hospitals, Ryan White clinics, and State AIDS Drug Assistance Programs.
Inflectra began shipping to wholesalers in late November 2016, and can now be ordered from wholesalers across the country.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.